{"id":"cyclosporine-vehicle","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation / burning"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Foreign body sensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine suppresses the production of inflammatory cytokines by T lymphocytes through calcineurin inhibition, which prevents the transcription of IL-2 and other pro-inflammatory mediators. In ophthalmic formulations, it reduces ocular surface inflammation and increases tear production, making it effective for dry eye disease where immune-mediated inflammation is a primary pathogenic mechanism.","oneSentence":"Cyclosporine is an immunosuppressant that inhibits T-cell activation by blocking calcineurin, thereby reducing inflammatory responses in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:21.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"},{"name":"Ocular surface inflammation"}]},"trialDetails":[{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT07234318","phase":"","title":"Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-12-15","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT06766357","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease","status":"RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-04-03","conditions":"Moderate to Severe Dry Eye","enrollment":360},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT04144413","phase":"PHASE3","title":"3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-05-31","conditions":"Dry Eye Disease With Severe Keratitis","enrollment":350},{"nctId":"NCT06348602","phase":"PHASE1, PHASE2","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-08-01","conditions":"Ocular Graft-versus-host Disease","enrollment":60},{"nctId":"NCT04362670","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2020-04-23","conditions":"Dry Eye Disease","enrollment":153},{"nctId":"NCT04523142","phase":"PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2021-01-04","conditions":"Dry Eye Disease (DED)","enrollment":202},{"nctId":"NCT04523129","phase":"PHASE3","title":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-12-05","conditions":"Dry Eye Disease","enrollment":834},{"nctId":"NCT04812951","phase":"EARLY_PHASE1","title":"Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2021-02-17","conditions":"Ocular Surface Disease, Ocular Inflammation","enrollment":101},{"nctId":"NCT05322148","phase":"PHASE3","title":"Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2022-06-03","conditions":"Dry Eye","enrollment":59},{"nctId":"NCT03292809","phase":"PHASE2, PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2017-10-19","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT02688556","phase":"PHASE3","title":"Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-02","conditions":"Keratoconjunctivitis Sicca","enrollment":745},{"nctId":"NCT01751126","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2013-04-29","conditions":"Vernal Keratoconjunctivitis","enrollment":169},{"nctId":"NCT00328653","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2006-05","conditions":"Conjunctivitis, Vernal","enrollment":118},{"nctId":"NCT02845674","phase":"PHASE3","title":"An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-07-29","conditions":"Keratoconjunctivitis Sicca","enrollment":258},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT02013791","phase":"PHASE2","title":"Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-04-29","conditions":"Dry Eye Syndromes","enrollment":55},{"nctId":"NCT02865356","phase":"PHASE2","title":"Topical Solution for the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Spherium Biomed","startDate":"2016-09","conditions":"Atopic Dermatitis","enrollment":36},{"nctId":"NCT02917512","phase":"PHASE2","title":"Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-03","conditions":"Dry Eye Syndrome","enrollment":114},{"nctId":"NCT01064830","phase":"PHASE2","title":"Topical Cyclosporine Suspension for the Treatment of Brittle Nails","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-02","conditions":"Brittle Nail Syndrome","enrollment":21},{"nctId":"NCT00739349","phase":"PHASE2","title":"NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-08","conditions":"Dry Eye","enrollment":132},{"nctId":"NCT02113293","phase":"PHASE1","title":"CyclASol® Phase 1 Study","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2014-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT00991458","phase":"PHASE2","title":"Study of Cyclosporine in Post-LASIK Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-10","conditions":"Laser In Situ Keratomileusis","enrollment":621},{"nctId":"NCT01850979","phase":"PHASE4","title":"Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-02","conditions":"Sjogren Syndrome, Dry Eye Syndrome","enrollment":24},{"nctId":"NCT00784719","phase":"PHASE1, PHASE2","title":"A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Dry Eye Syndromes","enrollment":327},{"nctId":"NCT00884585","phase":"PHASE3","title":"Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-05","conditions":"Atopic Conjunctivitis","enrollment":176},{"nctId":"NCT01109056","phase":"PHASE2","title":"Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Pterygium","enrollment":115},{"nctId":"NCT01120132","phase":"PHASE2","title":"Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":716},{"nctId":"NCT00833495","phase":"PHASE2","title":"Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2009-01","conditions":"Allergic Conjunctivitis","enrollment":155},{"nctId":"NCT00814515","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2007-09","conditions":"Moderate to Severe Dry Eye Syndrome","enrollment":482},{"nctId":"NCT00578370","phase":"PHASE1, PHASE2","title":"Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"ISDIN","startDate":"2007-11","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT00001731","phase":"PHASE2","title":"Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1997-11","conditions":"Keratoconjunctivitis Sicca, Sjogren's Syndrome","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cyclosporine Vehicle","genericName":"Cyclosporine Vehicle","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine is an immunosuppressant that inhibits T-cell activation by blocking calcineurin, thereby reducing inflammatory responses in the eye. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}